JP2023508202A5 - - Google Patents
Info
- Publication number
- JP2023508202A5 JP2023508202A5 JP2022539245A JP2022539245A JP2023508202A5 JP 2023508202 A5 JP2023508202 A5 JP 2023508202A5 JP 2022539245 A JP2022539245 A JP 2022539245A JP 2022539245 A JP2022539245 A JP 2022539245A JP 2023508202 A5 JP2023508202 A5 JP 2023508202A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060823A JP7875406B2 (ja) | 2019-12-24 | 2023-04-04 | ＴＧＦ－βＲＩＩ結合タンパク質 |
| JP2025018365A JP2025083342A (ja) | 2019-12-24 | 2025-02-06 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2024576 | 2019-12-24 | ||
| NL2024576 | 2019-12-24 | ||
| PCT/NL2020/050813 WO2021133167A1 (en) | 2019-12-24 | 2020-12-22 | Tgf-beta-rii binding proteins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060823A Division JP7875406B2 (ja) | 2019-12-24 | 2023-04-04 | ＴＧＦ－βＲＩＩ結合タンパク質 |
| JP2025018365A Division JP2025083342A (ja) | 2019-12-24 | 2025-02-06 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508202A JP2023508202A (ja) | 2023-03-01 |
| JP2023508202A5 true JP2023508202A5 (enExample) | 2023-04-25 |
| JP7633259B2 JP7633259B2 (ja) | 2025-02-19 |
Family
ID=69700252
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539245A Active JP7633259B2 (ja) | 2019-12-24 | 2020-12-22 | ＴＧＦ－βＲＩＩ結合タンパク質 |
| JP2023060823A Active JP7875406B2 (ja) | 2019-12-24 | 2023-04-04 | ＴＧＦ－βＲＩＩ結合タンパク質 |
| JP2025018365A Pending JP2025083342A (ja) | 2019-12-24 | 2025-02-06 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060823A Active JP7875406B2 (ja) | 2019-12-24 | 2023-04-04 | ＴＧＦ－βＲＩＩ結合タンパク質 |
| JP2025018365A Pending JP2025083342A (ja) | 2019-12-24 | 2025-02-06 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12570747B2 (enExample) |
| EP (2) | EP4269433A3 (enExample) |
| JP (3) | JP7633259B2 (enExample) |
| KR (2) | KR20220117267A (enExample) |
| CN (3) | CN116199780A (enExample) |
| AR (2) | AR120914A1 (enExample) |
| AU (4) | AU2020412201B2 (enExample) |
| BR (1) | BR112022012522A2 (enExample) |
| IL (2) | IL294181A (enExample) |
| MX (2) | MX2022007919A (enExample) |
| PH (1) | PH12022551527A1 (enExample) |
| TW (2) | TW202128747A (enExample) |
| WO (1) | WO2021133167A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116199780A (zh) | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| MX2024006018A (es) * | 2021-11-19 | 2024-07-29 | Merus Nv | Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii. |
| CN120731229A (zh) | 2022-12-20 | 2025-09-30 | 美勒斯公司 | FAP结合域以及结合FAP和TGF-βRII的双特异性结合部分 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| EP3456191A1 (en) | 2008-06-27 | 2019-03-20 | Merus N.V. | Antibody producing non-human mammals |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| US9150651B2 (en) | 2011-01-06 | 2015-10-06 | Glaxo Group Limited | Single variable domain immunoglobulins that bind TGF-beta receptor II |
| BR112015006824A2 (pt) | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| JP2018527903A (ja) | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | Ｇｄｆ１１結合タンパク質およびその使用 |
| TW201825519A (zh) * | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| CA3094318A1 (en) | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
| CN116199780A (zh) | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
-
2020
- 2020-12-22 CN CN202211726462.2A patent/CN116199780A/zh active Pending
- 2020-12-22 MX MX2022007919A patent/MX2022007919A/es unknown
- 2020-12-22 BR BR112022012522A patent/BR112022012522A2/pt unknown
- 2020-12-22 IL IL294181A patent/IL294181A/en unknown
- 2020-12-22 EP EP23189839.6A patent/EP4269433A3/en active Pending
- 2020-12-22 WO PCT/NL2020/050813 patent/WO2021133167A1/en not_active Ceased
- 2020-12-22 CN CN202080094188.4A patent/CN115038497A/zh active Pending
- 2020-12-22 EP EP20829233.4A patent/EP4081306A1/en active Pending
- 2020-12-22 CN CN202211726434.0A patent/CN116375869A/zh active Pending
- 2020-12-22 KR KR1020227023748A patent/KR20220117267A/ko active Pending
- 2020-12-22 PH PH1/2022/551527A patent/PH12022551527A1/en unknown
- 2020-12-22 AU AU2020412201A patent/AU2020412201B2/en active Active
- 2020-12-22 US US17/757,953 patent/US12570747B2/en active Active
- 2020-12-22 KR KR1020237034290A patent/KR20230145542A/ko active Pending
- 2020-12-22 JP JP2022539245A patent/JP7633259B2/ja active Active
- 2020-12-23 TW TW109145819A patent/TW202128747A/zh unknown
- 2020-12-23 TW TW112150430A patent/TW202417513A/zh unknown
- 2020-12-23 AR ARP200103661A patent/AR120914A1/es unknown
-
2022
- 2022-06-23 MX MX2024002182A patent/MX2024002182A/es unknown
-
2023
- 2023-02-13 AU AU2023200779A patent/AU2023200779B2/en active Active
- 2023-04-04 JP JP2023060823A patent/JP7875406B2/ja active Active
- 2023-07-09 IL IL304317A patent/IL304317A/en unknown
- 2023-11-07 AR ARP230102989A patent/AR130991A2/es unknown
-
2025
- 2025-02-06 JP JP2025018365A patent/JP2025083342A/ja active Pending
-
2026
- 2026-05-11 AU AU2026203599A patent/AU2026203599A1/en active Pending
- 2026-05-18 AU AU2026203807A patent/AU2026203807A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11578131B2 (en) | Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules | |
| JP7273110B2 (ja) | 高親和性抗ｖｅｇｆ抗体 | |
| EP3889172B1 (en) | Targeted tgf beta inhibition | |
| AU2024200261A1 (en) | Anti-DR5 antibodies and methods of use thereof | |
| CN103562223B (zh) | 抗c‑Met抗体 | |
| JP2020513809A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP2022507679A (ja) | Ｈｅｒ２／ｐｄ１二重特異性抗体 | |
| JP2018503365A5 (enExample) | ||
| US20240117035A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| US11008387B2 (en) | Antibody inhibiting binding of VEGF to NRP1 | |
| JP2025004078A (ja) | ４－１ｂｂ結合タンパク質及びその用途 | |
| JP2023076596A5 (enExample) | ||
| JP2023510429A (ja) | 抗ガレクチン－９抗体およびその使用 | |
| CA3148291A1 (en) | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies | |
| JP2023506593A5 (enExample) | ||
| RU2857760C2 (ru) | Фармацевтическая композиция для лечения рака, включающая слитый белок, включающий il-12 и антитело против fap, и противоопухолевое средство | |
| CN112805068A (zh) | 靶向cd137的抗体及其使用方法 | |
| KR20220160512A (ko) | Ox40 작용제 및 그의 용도 | |
| HK40108283A (en) | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof | |
| HK1231904A1 (en) | Targeted tgf beta inhibition | |
| HK1231904B (en) | Targeted tgf beta inhibition | |
| HK1197919A (en) | Anti-fgfr2 antibodies and uses thereof |